Sentences with phrase «therapy trials funded»

The proposed clinical trial, in which researchers would use CRISPR to engineer immune cells to fight cancer, won approval from the Recombinant DNA Advisory Committee (RAC) at the U.S. National Institutes of Health, a panel that has traditionally vetted the safety and ethics of gene therapy trials funded by the U.S. government and others.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Revenue from selling Celgene's therapies will fund the company's late - stage pipeline, which boasts three new cancer therapy candidates in pivotal trials.

The results from the Cancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone therapy.

Clinical trials that charge enrollees to participate are ostensibly aimed at giving patients early access to promising therapies — often in the fields of stem cells or aging reversal — that are too unusual or have too little profit potential to get funding from traditional sources such as companies, foundations, or the National Institutes of Health.

Researchers in US and Canada funded by the Cooperative Studies Program of the Department of Veterans Affairs and the Canadian Institutes for Health Research compared the costs and benefits of etanercept - methotrexate first versus triple therapy first in 353 patients enrolled in the RACAT trial who continued to have uncontrolled symptoms of RA after at least 12 weeks of methotrexate therapy.

Dr Elliott, who is part - funded by Parkinson's UK, said: «If this kind of drug proves to be successful in clinical trials, it would have the potential to bring long - lasting relief from PD symptoms and fewer side effects than existing levadopa therapy.»

Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.

The series started in 2009, when the U.S. government funded a team of researchers to recruit and study participants for the Testosterone Trial — a group of seven long - term studies of how testosterone therapy affects sexual activity, energy level, memory, heart and bone health, and the ability to walk a certain distance.

Lin and colleagues have started a company to develop the new therapy and have raised initial funding for clinical trials.

It is also funding research aimed at a stem cell - based therapy for Parkinson's disease that is expected to lead to a clinical trial.

@Ham: The startup is venture funded, which means the people involved most likely think they are only a year or two away from therapies that will work in people, ready for trials to begin.

Dr. Falk is also PI of an NIH, pharma, and philanthropic funded translational research laboratory group at CHOP that investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and human tissue models of genetic - based respiratory chain dysfunction, and directs multiple clinical treatment trials in mitochondrial disease patients.

Individuals who are diabetic and have suffered a cardiac event may benefit from chelation therapy; the Trial to Access Chelation Therapy study which was funded by the National Institutes for Health suggests that chelation therapy may significantly reduce a recurrent cardiactherapy; the Trial to Access Chelation Therapy study which was funded by the National Institutes for Health suggests that chelation therapy may significantly reduce a recurrent cardiacTherapy study which was funded by the National Institutes for Health suggests that chelation therapy may significantly reduce a recurrent cardiactherapy may significantly reduce a recurrent cardiac event.

This analysis of the NIH - funded Trial to Assess Chelation Therapy (TACT) focuses on the comparison of 2 treatment groups chelation + MV versus placebo infusions + placebo MV, evaluating a treatment strategy reflecting clinical practice, and not previously presented in detail.

The National Institute of Health, a government agency (not funded by pharmaceutical grants) conducted a clinical trial to see if desiccated thyroid therapy is advantageous to T4 alone (8) The authors of the study concluded: «DTE (Desiccated Thyroid Extract) therapy did not result in a significant improvement in quality of life; however, DTE caused modest weight loss and nearly half (48.6 %) of the study patients expressed preference for DTE over l - T4 (Levothyroxine).

With the funding, the organization hopes to implement: clinical trials to test new innovative therapies to help save dogs and alleviate dog suffering now, prevention studies related to genetics and canine genome, incorporating lifetime risk, funding of a tumor tissue bank, and establishment of an endowment to guarantee continued research efforts.

AGTC plans to use the net proceeds of the offering to fund preclinical investigation and Phase 1/2 trials of potential product candidates for treatment of wet AMD; to expand its manufacturing capabilities and create a pilot manufacturing group; to in - license, acquire or invest in complementary gene therapy, technologies, products or assets; and for working capital and other general corporate purposes.

The Self - Harm Intervention: Family Therapy (SHIFT) Trial was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (grant no. 07/33/01) following a commissioned call for this research.

The Family Therapy intervention was based on a modified version of the Leeds Family Therapy & Research Centre Systemic Family Therapy Manual (LFTRC Manual), the development and validation of which was funded by the Medical Research Council (MRC) to support trials of FT [45].